Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy: The Positive Impact of Adjuvant Radiotherapy

Luigi F. Da Pozzo, Cesare Cozzarini, Alberto Briganti, Nazareno Suardi, Andrea Salonia, Roberto Bertini, Andrea Gallina, Marco Bianchi, Gemma V. Fantini, Angelo Bolognesi, Ferruccio Fazio, Francesco Montorsi, Patrizio Rigatti

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Background: Recent large, prospective, randomised studies have demonstrated that adjuvant radiotherapy (RT) is a safe and effective procedure for preventing disease recurrence in locally advanced prostate cancer (PCa) patients. However, no study has ever tested the role of adjuvant RT in node-positive patients after radical prostatectomy (RP). Objective: We hypothesised that adjuvant RT with early hormone therapy (HT) might improve long-term outcomes of patients with PCa and nodal metastases treated with RP and extended pelvic lymph node dissection (ePLND). Design, setting, and participants: This retrospective study included 250 consecutive patients with pathologic lymph node invasion. We assessed factors predicting long-term biochemical recurrence (BCR)-free and cancer-specific survival (CSS) in node-positive PCa patients treated with RP, ePLND, and adjuvant treatments between 1988 and 2002 in a tertiary academic centre. Intervention: All patients received adjuvant treatments according to the treating physician after detailed patient information: 129 patients (51.6%) were treated with a combination of RT and HT, while 121 patients (48.4%) received adjuvant HT alone. Measurements: BCR-free survival and CSS in patients with node-positive PCa. Results and limitations: Mean follow-up was 95.9 mo (median: 91.2). BCR-free survival and CSS rates at 5, 8, and 10 yr were 72%, 61%, 53% and 89%, 83%, 80%, respectively. In multivariable Cox regression models, adjuvant RT and the number of positive nodes were independent predictors of BCR-free survival (p = 0.002 and p = 0.003, respectively) as well as of CSS (p = 0.009 and p = 0.01, respectively). Moreover, there was significant gain in predictive accuracy when adjuvant RT was included in multivariable models predicting BCR-free survival and CSS (gain: 3.3% and 3%, respectively; all p <0.001). Conclusions: Our data showed excellent long-term outcome for node-positive PCa patients treated with radical surgery plus adjuvant treatments. This study is the first to report a significant protective role for adjuvant RT in BCR-free survival and CSS of node-positive patients.

Original languageEnglish
Pages (from-to)1003-1011
Number of pages9
JournalEuropean Urology
Volume55
Issue number5
DOIs
Publication statusPublished - May 2009

Fingerprint

Adjuvant Radiotherapy
Prostatectomy
Lymph Node Excision
Prostatic Neoplasms
Neoplasm Metastasis
Survival
Recurrence
Neoplasms
Hormones
Therapeutics
Secondary Prevention
Proportional Hazards Models
Radiotherapy
Survival Rate
Retrospective Studies
Lymph Nodes

Keywords

  • Adjuvant radiotherapy
  • Lymph node metastases
  • Prostate cancer
  • Radical prostatectomy

ASJC Scopus subject areas

  • Urology

Cite this

Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy : The Positive Impact of Adjuvant Radiotherapy. / Da Pozzo, Luigi F.; Cozzarini, Cesare; Briganti, Alberto; Suardi, Nazareno; Salonia, Andrea; Bertini, Roberto; Gallina, Andrea; Bianchi, Marco; Fantini, Gemma V.; Bolognesi, Angelo; Fazio, Ferruccio; Montorsi, Francesco; Rigatti, Patrizio.

In: European Urology, Vol. 55, No. 5, 05.2009, p. 1003-1011.

Research output: Contribution to journalArticle

@article{b3667820dbe74956b4341b963fc607dc,
title = "Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy: The Positive Impact of Adjuvant Radiotherapy",
abstract = "Background: Recent large, prospective, randomised studies have demonstrated that adjuvant radiotherapy (RT) is a safe and effective procedure for preventing disease recurrence in locally advanced prostate cancer (PCa) patients. However, no study has ever tested the role of adjuvant RT in node-positive patients after radical prostatectomy (RP). Objective: We hypothesised that adjuvant RT with early hormone therapy (HT) might improve long-term outcomes of patients with PCa and nodal metastases treated with RP and extended pelvic lymph node dissection (ePLND). Design, setting, and participants: This retrospective study included 250 consecutive patients with pathologic lymph node invasion. We assessed factors predicting long-term biochemical recurrence (BCR)-free and cancer-specific survival (CSS) in node-positive PCa patients treated with RP, ePLND, and adjuvant treatments between 1988 and 2002 in a tertiary academic centre. Intervention: All patients received adjuvant treatments according to the treating physician after detailed patient information: 129 patients (51.6{\%}) were treated with a combination of RT and HT, while 121 patients (48.4{\%}) received adjuvant HT alone. Measurements: BCR-free survival and CSS in patients with node-positive PCa. Results and limitations: Mean follow-up was 95.9 mo (median: 91.2). BCR-free survival and CSS rates at 5, 8, and 10 yr were 72{\%}, 61{\%}, 53{\%} and 89{\%}, 83{\%}, 80{\%}, respectively. In multivariable Cox regression models, adjuvant RT and the number of positive nodes were independent predictors of BCR-free survival (p = 0.002 and p = 0.003, respectively) as well as of CSS (p = 0.009 and p = 0.01, respectively). Moreover, there was significant gain in predictive accuracy when adjuvant RT was included in multivariable models predicting BCR-free survival and CSS (gain: 3.3{\%} and 3{\%}, respectively; all p <0.001). Conclusions: Our data showed excellent long-term outcome for node-positive PCa patients treated with radical surgery plus adjuvant treatments. This study is the first to report a significant protective role for adjuvant RT in BCR-free survival and CSS of node-positive patients.",
keywords = "Adjuvant radiotherapy, Lymph node metastases, Prostate cancer, Radical prostatectomy",
author = "{Da Pozzo}, {Luigi F.} and Cesare Cozzarini and Alberto Briganti and Nazareno Suardi and Andrea Salonia and Roberto Bertini and Andrea Gallina and Marco Bianchi and Fantini, {Gemma V.} and Angelo Bolognesi and Ferruccio Fazio and Francesco Montorsi and Patrizio Rigatti",
year = "2009",
month = "5",
doi = "10.1016/j.eururo.2009.01.046",
language = "English",
volume = "55",
pages = "1003--1011",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Long-Term Follow-up of Patients with Prostate Cancer and Nodal Metastases Treated by Pelvic Lymphadenectomy and Radical Prostatectomy

T2 - The Positive Impact of Adjuvant Radiotherapy

AU - Da Pozzo, Luigi F.

AU - Cozzarini, Cesare

AU - Briganti, Alberto

AU - Suardi, Nazareno

AU - Salonia, Andrea

AU - Bertini, Roberto

AU - Gallina, Andrea

AU - Bianchi, Marco

AU - Fantini, Gemma V.

AU - Bolognesi, Angelo

AU - Fazio, Ferruccio

AU - Montorsi, Francesco

AU - Rigatti, Patrizio

PY - 2009/5

Y1 - 2009/5

N2 - Background: Recent large, prospective, randomised studies have demonstrated that adjuvant radiotherapy (RT) is a safe and effective procedure for preventing disease recurrence in locally advanced prostate cancer (PCa) patients. However, no study has ever tested the role of adjuvant RT in node-positive patients after radical prostatectomy (RP). Objective: We hypothesised that adjuvant RT with early hormone therapy (HT) might improve long-term outcomes of patients with PCa and nodal metastases treated with RP and extended pelvic lymph node dissection (ePLND). Design, setting, and participants: This retrospective study included 250 consecutive patients with pathologic lymph node invasion. We assessed factors predicting long-term biochemical recurrence (BCR)-free and cancer-specific survival (CSS) in node-positive PCa patients treated with RP, ePLND, and adjuvant treatments between 1988 and 2002 in a tertiary academic centre. Intervention: All patients received adjuvant treatments according to the treating physician after detailed patient information: 129 patients (51.6%) were treated with a combination of RT and HT, while 121 patients (48.4%) received adjuvant HT alone. Measurements: BCR-free survival and CSS in patients with node-positive PCa. Results and limitations: Mean follow-up was 95.9 mo (median: 91.2). BCR-free survival and CSS rates at 5, 8, and 10 yr were 72%, 61%, 53% and 89%, 83%, 80%, respectively. In multivariable Cox regression models, adjuvant RT and the number of positive nodes were independent predictors of BCR-free survival (p = 0.002 and p = 0.003, respectively) as well as of CSS (p = 0.009 and p = 0.01, respectively). Moreover, there was significant gain in predictive accuracy when adjuvant RT was included in multivariable models predicting BCR-free survival and CSS (gain: 3.3% and 3%, respectively; all p <0.001). Conclusions: Our data showed excellent long-term outcome for node-positive PCa patients treated with radical surgery plus adjuvant treatments. This study is the first to report a significant protective role for adjuvant RT in BCR-free survival and CSS of node-positive patients.

AB - Background: Recent large, prospective, randomised studies have demonstrated that adjuvant radiotherapy (RT) is a safe and effective procedure for preventing disease recurrence in locally advanced prostate cancer (PCa) patients. However, no study has ever tested the role of adjuvant RT in node-positive patients after radical prostatectomy (RP). Objective: We hypothesised that adjuvant RT with early hormone therapy (HT) might improve long-term outcomes of patients with PCa and nodal metastases treated with RP and extended pelvic lymph node dissection (ePLND). Design, setting, and participants: This retrospective study included 250 consecutive patients with pathologic lymph node invasion. We assessed factors predicting long-term biochemical recurrence (BCR)-free and cancer-specific survival (CSS) in node-positive PCa patients treated with RP, ePLND, and adjuvant treatments between 1988 and 2002 in a tertiary academic centre. Intervention: All patients received adjuvant treatments according to the treating physician after detailed patient information: 129 patients (51.6%) were treated with a combination of RT and HT, while 121 patients (48.4%) received adjuvant HT alone. Measurements: BCR-free survival and CSS in patients with node-positive PCa. Results and limitations: Mean follow-up was 95.9 mo (median: 91.2). BCR-free survival and CSS rates at 5, 8, and 10 yr were 72%, 61%, 53% and 89%, 83%, 80%, respectively. In multivariable Cox regression models, adjuvant RT and the number of positive nodes were independent predictors of BCR-free survival (p = 0.002 and p = 0.003, respectively) as well as of CSS (p = 0.009 and p = 0.01, respectively). Moreover, there was significant gain in predictive accuracy when adjuvant RT was included in multivariable models predicting BCR-free survival and CSS (gain: 3.3% and 3%, respectively; all p <0.001). Conclusions: Our data showed excellent long-term outcome for node-positive PCa patients treated with radical surgery plus adjuvant treatments. This study is the first to report a significant protective role for adjuvant RT in BCR-free survival and CSS of node-positive patients.

KW - Adjuvant radiotherapy

KW - Lymph node metastases

KW - Prostate cancer

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=62649087473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62649087473&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2009.01.046

DO - 10.1016/j.eururo.2009.01.046

M3 - Article

C2 - 19211184

AN - SCOPUS:62649087473

VL - 55

SP - 1003

EP - 1011

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -